Sep 27, 2024
Most cancer drugs must now be tested in paediatric cancers — unique PDX models can help
Approximately 75% of anticancer drugs must be tested against paediatric cancer. Drug developers can now use a database of patient-derived...
Sep 26, 2024
The unseen struggles of single parents navigating childhood cancer
Parenthood is often seen as one of the most challenging roles, but when childhood cancer becomes part of that reality, the demands and...
Sep 25, 2024
Supporting oncology patients with neurocognitive late effects
Here, CHOC psychologists Drs. Tiffany Torigoe-Lai and Eric Proffitt , along with CHOC neuropsychologist Dr. Diana Cohen, provide an...
Sep 24, 2024
Healing Without Harm: Reducing Chemo Toxicities
“One thing we can do to really help patients with cancer is to make chemotherapy safer without reducing its effectiveness. I believe this...
Sep 23, 2024
The Journey to Holistic Care for Childhood Cancer Patients
As oncologists and the healthcare industry advance their practices to propel care for children, it is crucial for the industry and...
Sep 20, 2024
Breast cancer drug could help prolong survival for children with brain tumors, study finds
A drug called ribociclib, currently used to treat breast cancer , could slow the progression of certain pediatric high-grade gliomas, an...
Sep 18, 2024
Drug discovery could prevent spread of childhood bone cancer
Now, scientists at the University of British Columbia have identified a potential drug that could halt osteosarcoma's spread. In a study...
Sep 17, 2024
Childhood cancer treatments increase keratinocyte carcinoma risk among survivors
Radiotherapy and hematopoietic cell transplant increased the risk for keratinocyte carcinoma development in childhood cancer survivors,...
Sep 16, 2024
Strength in numbers: Cooperative group clinical trials move the needle against pediatric cancer
Running a clinical trial requires enough patient participants to gather robust data so that researchers can draw appropriate conclusions...
Sep 13, 2024
FDA Grants Orphan Drug Designation to Opaganib in Neuroblastoma
The FDA has granted a second orphan drug designation to opaganib in oncology, this time for patients with neuroblastoma. Read more:...